Optimi Health (NASDAQ:OPTH) Upgraded by Zacks Research to Hold Rating

Zacks Research upgraded shares of Optimi Health (NASDAQ:OPTH) to a hold rating in a research report sent to investors on Thursday,Zacks.com reports.

Separately, Weiss Ratings initiated coverage on shares of Optimi Health in a research report on Thursday, May 21st. They set a “sell (d-)” rating on the stock. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Reduce”.

Optimi Health Stock Performance

NASDAQ:OPTH opened at $5.97 on Thursday. Optimi Health has a twelve month low of $4.95 and a twelve month high of $6.40.

More Optimi Health News

Here are the key news stories impacting Optimi Health this week:

• Positive Sentiment: Australia’s updated Authorized Prescriber framework broadens access to psychedelic-assisted therapy, potentially increasing demand for Optimi’s psilocybin and MDMA products in a key regulated market. Article Title
• Neutral Sentiment: Diamond Equity initiated/updated earnings estimates for multiple periods, showing expectations for continued net losses rather than an immediate path to profitability. Article Title